[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-350980-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-350980-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","the-clinical-landscape-of-pole-mutant-colorectal-cancer-a-retrospective-analysis-of-real-world-outcome","The clinical landscape of POLE-mutant colorectal cancer - a retrospective analysis of real-world outcome","","This retrospective analysis investigates the clinical landscape of colorectal cancer (CRC) driven by pathogenic POLE mutations, motivated by the role of POLE proofreading defects in generating high tumor mutation burden and neoantigens. A real-world cohort of CRC patients was compared between POLE-mutant and POLE wild-type groups for clinicopathological features, genomic profiles, and prognostic outcomes, including immunotherapy response in metastatic cases. POLE-mutant tumors show distinct hypermutated features and improved outcomes with immune checkpoint inhibitors in selected settings.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/the-clinical-landscape-of-pole-mutant-colorectal-cancer-a-retrospective-analysis-of-real-world-outcome/350980/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/the-clinical-landscape-of-pole-mutant-colorectal-cancer-a-retrospective-analysis-of-real-world-outcome/350980.png","ImageObject",300,407,{"name":42,"@type":43},"Aria","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes POLE-mutant colorectal cancer biologically distinct?","Question",{"text":63,"@type":64},"Pathogenic POLE mutations disrupt DNA proofreading, leading to a hypermutated phenotype with elevated tumor mutation burden and increased tumor neoantigen generation.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How common are pathogenic POLE mutations in the studied CRC cohort?",{"text":68,"@type":64},"Among 35,108 CRC patients, pathogenic POLE mutations were identified in 261 individuals, representing 0.74% of the cohort.",{"name":70,"@type":61,"acceptedAnswer":71},"Do pathogenic POLE mutations affect prognosis and immunotherapy benefit?",{"text":72,"@type":64},"In stage II CRC, POLE mutations were linked to a reduced recurrence risk versus POLE wild-type, and in metastatic disease, immune checkpoint inhibitors in first-line regimens improved progression-free survival and overall survival in patients with pathogenic POLE mutations.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},350980,1790168067,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Xu etal. BMC Medicine (2026) 24:83  \n[https://doi.org/10.1186/s12916-025-04611-z](https://doi.org/10.1186/s12916-025-04611-z)  \nBMC Medicine  \n RESEARCH Open Access  \nThe clinical landscape of POLE-mutant colorectal cancer: a retrospective analysis of real-world outcome  \nTing Xu1†, Xuhui Zhang1†, Zhenghang Wang1, Lin Shen1*, Xicheng Wang1* and Jian Li 1*  \nAbstract  \nBackground Pathogenic mutations in the POLE gene disrupt its proofreading function during DNA replication, causing an accumulation of erroneous nucleotide incorporations. This defect leads to a significantly elevated tumor mutation burden (TMB) and increased generation of tumor neoantigens. These molecular characteristics suggest a potential association between POLE-mutant tumors and distinct prognostic outcomes in colorectal cancer (CRC); however, clinical evidence supporting this correlation remains limited.  \nMethods We retrospectively collected a cohort of CRC patients harboring pathogenic POLE mutations. Comparative analyses were performed between POLE-mutant and POLE wild-type CRCs regarding their clinical characteristics, prognostic outcomes, and genomic profiles. Additionally, we evaluated the response to immunotherapy in metastatic POLE-mutant CRC cases.  \nResults Among 35,108 CRC patients, pathogenic POLE mutations were identified in 261 individuals, accounting for 0 . 74% of the cohort. The median age at diagnosis for POLE-mutant patients was 48 years, with a male predominance (74 .4%) and a substantial proportion (50 .4%) of tumors localized in the right-sided colon. All patients with pathogenic POLE mutations exhibited hypermutated phenotypes, characterized by a median TMB of 235.26 mutations per megabase (range: 71.20–719.00 mutations/Mb) . In stage II CRC, POLE mutations were significantly associated with a reduced risk of recurrence (hazard ratio [HR] 0. 344, 95% confidence interval [CI] 0 .157–0. 754, p = 0 . 008) when compared to POLE wild-type, microsatellite stable CRC patients. However, this association was not evident in stage III patients (HR 1. 004, 95% CI 0.490–2. 057, p = 0 . 992) . Importantly, the incorporation of immune checkpoint inhibitors in first-line treatment regimens significantly improved progression-free survival (HR = 0 . 247, 95% CI 0.117– 0. 552, p = 0 . 0002) and overall survival (HR = 0 . 317, 95% CI 0.103–1. 143, p = 0 . 0832) in metastatic CRC patients with pathogenic POLE mutations.  \nConclusions Pathogenic POLE-mutant CRC constitutes a relatively rare, yet clinically important, subtype. These cancers exhibit distinct clinicopathological and genomic features. Our results indicate that mutations in the POLE gene  \n†Ting Xu and Xuhui Zhang contributed equally to this study.  \n*Correspondence:  \nLin Shen [shenlin@bjmu.edu.cn](shenlin@bjmu.edu.cn)[ ](shenlin@bjmu.edu.cn)Xicheng Wang [Xicheng_wang@hotmail.com](Xicheng_wang@hotmail.com)[ ](Xicheng_wang@hotmail.com)Jian Li  \n[oncogene@163.com](oncogene@163.com)  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/","cbCainmahzS9nbEU","https://ap.wps.com/l/cbCainmahzS9nbEU","pdf",2341927,11,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Global CRC burden and immunotherapy context\n## Biological rationale for POLE mutations","[{\"question\":\"What makes POLE-mutant colorectal cancer biologically distinct?\",\"answer\":\"Pathogenic POLE mutations disrupt DNA proofreading, leading to a hypermutated phenotype with elevated tumor mutation burden and increased tumor neoantigen generation.\"},{\"question\":\"How common are pathogenic POLE mutations in the studied CRC cohort?\",\"answer\":\"Among 35,108 CRC patients, pathogenic POLE mutations were identified in 261 individuals, representing 0.74% of the cohort.\"},{\"question\":\"Do pathogenic POLE mutations affect prognosis and immunotherapy benefit?\",\"answer\":\"In stage II CRC, POLE mutations were linked to a reduced recurrence risk versus POLE wild-type, and in metastatic disease, immune checkpoint inhibitors in first-line regimens improved progression-free survival and overall survival in patients with pathogenic POLE mutations.\"}]","The clinical landscape of POLE-mutant colorectal cancer - a retrospective analysis of real-world outcome | PDF",1790092195,28,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/855de399c89a05582f7c80b91f975025.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d14f97cbd3351214b35c607fb18337b9.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/300b9dc40fb0ade6d401debf9c8b4924.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4880f8cae54e81b7747b90caf7c13cfe.webp",980,1301]